Vise Technologies Inc. Increases Holdings in Sanofi $SNY

Vise Technologies Inc. raised its stake in shares of Sanofi (NASDAQ:SNY) by 136.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 53,313 shares of the company’s stock after buying an additional 30,735 shares during the period. Vise Technologies Inc.’s holdings in Sanofi were worth $2,584,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Advisory Services Network LLC raised its stake in Sanofi by 1.4% during the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after buying an additional 210 shares during the last quarter. Waterfront Wealth Inc. raised its stake in Sanofi by 0.4% during the 3rd quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after buying an additional 214 shares during the last quarter. Savant Capital LLC raised its stake in Sanofi by 2.7% during the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after buying an additional 225 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in shares of Sanofi by 2.3% in the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after purchasing an additional 226 shares in the last quarter. Finally, Wesbanco Bank Inc. increased its stake in shares of Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after purchasing an additional 230 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on SNY shares. Morgan Stanley set a $52.00 price objective on Sanofi in a research note on Friday, May 1st. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Monday, April 20th. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi Trading Up 1.4%

Shares of Sanofi stock opened at $45.02 on Friday. The company has a market capitalization of $109.15 billion, a P/E ratio of 12.58, a P/E/G ratio of 1.11 and a beta of 0.34. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The company has a fifty day moving average of $45.45 and a 200 day moving average of $46.76. Sanofi has a fifty-two week low of $42.28 and a fifty-two week high of $52.68.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were issued a $2.4225 dividend. The ex-dividend date of this dividend was Monday, May 4th. This represents a yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is currently 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.